
14.2.2 Secondary endpoints

14.2.2.11 Discontinuation rate

Figure 14.2.2.11.1: Discontinuation rate from eligibility - Full Analysis Population



ContRuxo: Ruxolitinib continuous therapy. SCT: Allogeneic Stem cell therapy.

Table 14.2.2.11.1: Comparison of discontinuation rate at 3 years after start of investigational treatment between SCT and ContRuxo - Full Analysis Population

Timepoint	Treatment arm	Survival Function Estimate, S(t)	Standard Error	Absolute difference in S(t)	95% Lower confidence interval for absolute difference	95% Upper confidence interval for absolute difference	Z-value	P-value
3 years	ContRuxo	0.714	0.121	0.075	-0.184	0.334	0.568	0.57
	SCT	0.789	0.054					

ContRuxo: Ruxolitinib continuous therapy. SCT: Allogeneic Stem cell transplantation. 3 years defined as 3 years + 92 days after the date of inclusion to allow for Ruxolitinib induction period. All numerical values are rounded to 3 decimal places.
Standard error calculated using Greenwood's formula. Reference- Cantor AB. Projecting the standard error of the Kaplan-Meier estimator. Stat Med. 2001 Jul 30;20(14):2091-7. doi: 10.1002/sim.856. PMID: 11439423.

Page 1 of 1